Affiliation:
1. Discipline of Surgery, Lambe Institute for Translational Research, H91 TK33 Galway, Ireland
Abstract
Breast cancer is a heterogeneous disease highlighted by the presence of multiple tumor variants and the basal-like breast cancer (BLBC) is considered to be the most aggressive variant with limited therapeutics and a poor prognosis. Though the absence of detectable protein and hormonal receptors as biomarkers hinders early detection, the integration of genomic and transcriptomic profiling led to the identification of additional variants in BLBC. The high-throughput analysis of tissue-specific micro-ribonucleic acids (microRNAs/miRNAs) that are deemed to have a significant role in the development of breast cancer also displayed distinct expression profiles in each subtype of breast cancer and thus emerged to be a robust approach for the precise characterization of the BLBC subtypes. The classification schematic of breast cancer is still a fluid entity that continues to evolve alongside technological advancement, and the transcriptomic profiling of tissue-specific microRNAs is projected to aid in the substratification and diagnosis of the BLBC tumor subtype. In this review, we summarize the current knowledge on breast tumor classification, aim to collect comprehensive evidence based on the microRNA expression profiles, and explore their potential as prospective biomarkers of BLBC.
Funder
National Breast Cancer Research Institute [NBCRI]
HRB Summer student scholarship 2023
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference156 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021
2. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023
3. Testa, U., Castelli, G., and Pelosi, E. (2020). Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Med. Sci., 8.
4. Breast cancer heterogeneity and its implication in personalized precision therapy;Guo;Exp. Hematol. Oncol.,2023
5. Breast Cancer Classification Based on Proteotypes Obtained by SWATH Mass Spectrometry;Bouchal;Cell Rep.,2019